Cited by Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer

The Potential Role of PD-1/PD-L1 Small Molecule Inhibitors in Colorectal Cancer with Different Mechanisms of Action DOI

Suhaibee Kuno,

Nattaporn Pakpian,

Chatchai Muanprasat

и другие.

European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177351 - 177351

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors DOI

Fei Du, Guojun Wang, Qian Dai

и другие.

Biomarker Research, Год журнала: 2025, Номер 13(1)

Опубликована: Фев. 26, 2025

Abstract The battle against cancer has evolved over centuries, from the early stages of surgical resection to contemporary treatments including chemotherapy, radiation, targeted therapies, and immunotherapies. Despite significant advances in treatment recent decades, these therapies remain limited by various challenges. Immune checkpoint inhibitors (ICIs), a cornerstone tumor immunotherapy, have emerged as one most promising advancements treatment. Although ICIs, such CTLA-4 PD-1/PD-L1 inhibitors, demonstrated clinical efficacy, their therapeutic impact remains suboptimal due patient-specific variability immune resistance. Cell death is fundamental process for maintaining tissue homeostasis function. Recent research highlights that combination induced regulatory cell (RCD) ICIs can substantially enhance anti-tumor responses across multiple types. In cells exhibiting high levels recombinant solute carrier family 7 member 11 (SLC7A11) protein, glucose deprivation triggers programmed (PCD) pathway characterized disulfide bond formation REDOX (reduction-oxidation) reactions, termed “disulfidptosis.” Studies suggest disulfidptosis plays critical role efficacy SLC7A11 cancers. Therefore, investigate potential synergy between this study will explore mechanisms both processes progression, with goal enhancing response targeting intracellular pathway.

Язык: Английский

Процитировано

Encrypting Cancer’s Morse Code: The Synergistic Power of CD47-SIRP<i>α</i> Blockade and Tyrosine Kinase Inhibition DOI